Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward by Freeman, TP et al.
Dopamine, urges to smoke, and the relative salience
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When addicted individuals are exposed to drug-related stimuli, dopamine release is thought to mediate incentive salience attribution, increasing
attentional bias, craving and drug seeking. It is unclear whether dopamine acts specifically on drug cues versus other rewards, and if these effects
correspond with craving and other forms of cognitive bias. Here, we administered the dopamine D2/D3 agonist pramipexole (0.5mg) to 16 tobacco
smokers in a double-blind placebo-controlled crossover design. Visual fixations on smoking and money images were recorded alongside smoking urges
and fluency tasks. Pramipexole attenuated a marked bias in initial orienting towards smoking relative to money but did not alter a maintained
attentional bias towards smoking. Pramipexole decreased urges to smoke retrospectively after the task but not on a state scale. Fewer smoking
words were generated after pramipexole but phonological and semantic fluency were preserved. Although these treatment effects did not correlate with
each other, changes in initial orienting towards smoking and money were inversely related to baseline scores. In conclusion, pramipexole can reduce the
salience of an addictive drug compared with other rewards and elicit corresponding changes in smoking urges and cognitive bias. These reward-specific
and baseline-dependent effects support an inverted-U shaped profile of dopamine in addiction.
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INTRODUCTION
Drug addiction is often characterised by an increase in the incentive-
motivational properties of the drug alongside a reduction in the sali-
ence of other non-drug rewards such as money, food or sex (Anselme,
2009; Bu¨hler et al., 2010; Goldstein and Volkow, 2011). This imbalance
may be heightened during exposure to drug-related cues, which are
able to overshadow non-drug stimuli that are equally predictive of
financial reward (Freeman et al., 2012a). A strong drive to seek out
one’s drug of choice alongside a lack of motivation to engage in other
activities may consign addicted individuals to a recurring cycle of drug
use and relapse, especially when they are exposed to previous drug-
taking environments. Psychological treatments for addiction which
target drug-related and non-drug reward processes can be effective
(Petry, 2000; Curran and Drummond, 2005); however, the pharmaco-
logical mechanisms through which their relative salience might be
shifted are not well understood.
Dopamine release in response to drug-associated stimuli is thought to
change how these cues are perceived in addicted individuals, increasing
craving and playing a causal role in drug use (Robinson and Berridge,
1993; Franken, 2003). This process of incentive salience attribution can
be indexed as the extent to which drug cues capture selective attention,
or ‘attentional bias’ (Franken, 2003; Field and Cox, 2008). Attentional
bias to drug cues can predict relapse vulnerability (Waters et al., 2003;
Marissen et al., 2006; Janes et al., 2010; Powell et al., 2010; Garland et al.,
2012) and offers a viable target for improving the effectiveness of treat-
ment (Schoenmakers et al., 2010). Dopaminergic involvement in atten-
tional bias is supported by a number of experimental studies (Franken
et al., 2004; Munafo` et al., 2007; Hitsman et al., 2008; Ersche et al., 2010;
Luijten et al., 2012). According to a cognitive psychopharmacological
model of drug addiction (Franken, 2003), these effects should be accom-
panied by corresponding changes in drug-related craving and other
cognitive biases; however, empirical support for this is currently lacking
(Franken et al., 2004; Munafo` et al., 2007; Hitsman et al., 2008; Ersche
et al., 2010; Luijten et al., 2012).
Another issue is that previous studies supporting a role of dopamine
in drug-related attentional bias (Franken et al., 2004; Munafo` et al.,
2007; Hitsman et al., 2008; Ersche et al., 2010; Luijten et al., 2012) did
not examine the effects of these manipulations on the salience of non-
drug reward stimuli such as images of money, which can also elicit
attentional bias in drug users (Morgan et al., 2008). These effects
might be important clinically because the tendency to show weak re-
sponses to pleasant or reward-based images compared with drug-related
stimuli is predictive of frequency of drug use at follow-up (Lubman
et al., 2009) and chances of relapsing during a subsequent quit attempt
(Versace et al., 2011). The implications of these findings are that
pharmacological treatments, which aim to reduce the salience of
drug-related cues alone may not be optimal, unless they act to redress
an imbalance between the salience of the drug relative to that of non-
drug rewards (Bu¨hler et al., 2010).
Pramipexole is a dopamine D2/D3 agonist used for the treatment of
Parkinson’s disease and restless leg syndrome. At low doses, its effects
are indicative of preferential action at presynaptic autoreceptors rather
than post-synaptic receptors (Maj et al., 1997; Pizzagalli et al., 2008).
These autoreceptors respond to ‘tonic’ or background dopamine in a
self-regulatory manner, by reducing the short-latency, short-duration
‘phasic’ dopamine firing that occurs to behaviourally relevant stimuli
(Grace, 1991). Low dose pramipexole should therefore, through agon-
ist action at presynaptic autoreceptors, reduce the phasic release of
dopamine that occurs upon exposure to drug cues (Phillips et al.,
2003). Moreover, pramipexole acutely decreases regional cerebral
blood flow in the anterior cingulate cortex and insula (Black et al.,
2002), activation of which has been linked to attentional bias in smo-
kers (Janes et al., 2010; Luijten et al., 2011; Vollsta¨dt-Klein et al., 2011).
Taken together, this suggests that pramipexole should decrease atten-
tional bias to drug cues in smokers.
In this study, we examined whether a single low (0.5mg) dose of
pramipexole would reduce attentional bias towards smoking-related
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cues. Both initial orienting and maintained attention were recorded
because experimental manipulations have produced dissociable effects
on these measures in smokers (Field et al., 2004; Bradley et al., 2007).
We investigated whether similar or contrasting results would emerge
for images of money, because smokers may show an imbalance in the
salience of drug versus non-drug reward (Bu¨hler et al., 2010) and
effects of dopamine agonists can differ according to baseline perform-
ance (Cools and D’Esposito, 2011). Since modification of attentional
bias should be accompanied by corresponding changes in craving and
other cognitive bias (Franken, 2003), we hypothesised that pramipex-
ole would reduce tobacco craving and urges to smoke, which have
previously been reported after treatment with a dopamine agonist
(Caskey et al., 1999, 2002; Jarvik et al., 2000) and also ‘drug fluency’,
or the free generation of smoking words from memory, which is the-
oretically related to attentional bias (Goldstein et al., 2007).
MATERIALS AND METHODS
Design and participants
A randomized double-blind placebo-controlled crossover design was
used to assess the effects of 0.5mg pramipexole in 16 non-treatment-
seeking smokers (8men) recruited from the community. Inclusion
criteria were as follows: age 18–40 years, smoking 10 cigarettes per
day for 1 year, smoking a first cigarette 1 h after waking, normal or
corrected to normal vision and fluent spoken English. Exclusion cri-
teria were current use of any smoking cessation aid, a learning, mental
health or substance abuse problem other than nicotine, tumours of the
pituitary or adrenal gland, reduced liver or kidney function, pregnancy
or breast feeding. All participants provided written, informed consent.
This study was approved by the UCL Graduate School Ethics
Committee and conducted in accordance with the Declaration of
Helsinki. The tasks reported here formed part of a larger battery of
tests reported elsewhere (Freeman et al., 2012b).
Assessments
Visual probe task
Overt attention was recorded using an eye tracking device synchro-
nized to a computer-based task. After central fixation, two images were
presented side by side on screen. Both were 109-mm wide and 84-mm
high, with a distance of 58mm between their closest edges. They were
presented in pairs consisting of a ‘reward’ image and a ‘control’ image
matched for visual composition. For example in a smoking trial, a
woman smoking a cigarette (reward image) was shown next to a
woman applying lipstick (control image) and, in a money trial, UK
bank notes (reward image) were displayed next to train tickets (control
image). Two task versions were created using different stimulus sets to
control for changes in novelty across the two testing sessions. Each
version employed 8 buffer trials and 192 experimental trials, consisting
of 10 pairs of monetary images expanded from a previous stimulus set
(Morgan et al., 2008) and 10 pairs of smoking images and 4 pairs of
neutral filler images taken from Mogg et al. (2003) (Figure 1).
Immediately after stimulus offset, a blank screen was displayed with
a probe in the same location as one of the previous images (reward or
control). Participants were required to press a key corresponding to its
identity (either ‘up’ or ‘down’). No time limit or incentive was pro-
vided for responding to the probe. Faster reaction times (RTs) to re-
spond to probes appearing in the same location as a reward image
compared with a control image are indicative of attentional bias.
Participants were asked to take in both of the images on screen and
to respond to the probes as quickly and accurately as possible. Pairs of
images were either shown for 250 or 2000ms to index both initial
orienting and maintained attention using RTs (Morgan et al., 2010;
Freeman et al., 2012a). Each pair of images was presented four times
for 250ms and four times for 2000ms, interspersed throughout the
task. Reward/control images appeared equally often on the left and the
right and were replaced by the probe on an equal number of trials.
Probe identity (up or down) was balanced across trials. Trials were
randomised with a maximum of two trials from the same condition
(money, smoking or neutral) shown in succession.
Picture rating task
This task presented the same images used in the visual probe task
onscreen (109-mm wide and 84-mm high) and required participants
to rate them for their pleasantness on a 7-item scale from 3 (very
unpleasant) to þ3 (very pleasant).
Phonological, semantic and drug fluency
Participants were asked to name as many unique exemplars as possible
beginning with the same letter (M; phonological), from the same cat-
egory (fruit; semantic), and related to smoking (drug fluency) in that
order, based on Goldstein et al. (2007). Sixty seconds was provided for
each variant.
Mood and physical symptoms scale
This 7-item scale includes ‘Depression’, ‘Irritability’, ‘Restlessness’,
‘Hunger’ and ‘Poor Concentration’ which were rated ‘at this time’
from 0 (not at all) to 4 (extremely) (West and Hajek, 2004). Time
Spent with Urges (‘How much of the time have you felt the urge to
smoke in the past 2 hours?’) was rated from 0 (not at all) to 5 (all the
time) and Strength of Urges to Smoke (SUTS) (‘How strong have these
urges been?’) was rated from 0 (no urges) to 5 (extremely strong).
Tobacco craving questionnaire-short form
Each of the 12 items on this scale were rated ‘right now’ from 1
(strongly disagree) to 7 (strongly agree); higher scores reflect stronger
tobacco craving (Heishman et al., 2008). It has 4 subscales:
Emotionality e.g. ‘I would be less irritable now if I could smoke’,
Expectancy e.g. ‘I would enjoy a cigarette right now’, Compulsivity
e.g. ‘If I smoked right now, I would not be able to stop’, and
Purposefulness e.g. ‘If I had a lit cigarette in my hand, I would prob-
ably smoke it’.
Fig. 1 Visual probe task. Following central fixation, two stimuli were displayed side by side for
either 250 or 2000 ms. Experimental trials used smoking-related or money picture pairs, consisting of
a reward image (shown here on the right; money) and a matching control image (shown on the left;
train tickets). Eye tracking was used to determine the proportion of trials in which a first fixation
occurred towards reward versus control images (initial orienting) and the duration of fixations on
images across 2000 ms trials (maintained attentional bias). RTs to a probe at stimulus offset were
used as a behavioural measure of attentional bias.
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Fagerstro¤m test for nicotine dependence
This scale of nicotine dependence consists of six items that are rated
between 0 and 3, with scores ranging from 0 (low dependence) to 10
(high dependence) (Heatherton et al., 1991).
Motivation to stop scale
A single item combining desire and intention to quit smoking. Scores
range from 1 (I don’t want to stop smoking) to 7 (I REALLY want to
stop smoking and intend to in the next month) (Kotz et al., 2012).
Procedure
Following screening, participants attended two 3-h laboratory sessions
separated by a washout period lasting between 5 and 9 days.
Participants were asked to fast for an hour before attendance, to refrain
from caffeine consumption on the day of testing and to avoid driving
or using machinery for the remainder of day. After smoking a cigarette,
a carbon monoxide (CO) reading (Bedfont Micro Smokerlyzer, UK)
and baseline assessments (Mood and Physical Symptoms Scale
[MPSS], tobacco craving questionnaire-short form [TCQ-SF]) were
taken. This was followed by oral drug administration, which was
either 0.5mg pramipexole (peak plasma levels at 1–3 h) (Wright
et al., 1997) or matched placebo. Based on a previous experimental
design (Ersche et al., 2010), the peripheral D2 antagonist domperidone
(30mg) was co-administered on both days to reduce unwanted side
effects of dopamine agonist treatment such as nausea and vomiting
(Parkes, 1986). Smoking was not permitted for the remainder of each
test session, which was enforced by supervision. After drug adminis-
tration, participants were given trait questionnaires regarding mood
and smoking behavior that were split across the two testing days
[0–15min post-drug, including the Fagerstro¨m test for nicotine de-
pendence (FTND) and motivation to stop scale (MTSS)] and were
encouraged to read magazines or books provided (15–90min post-
drug) before testing began (90 min post-drug). Assessments were
conducted in the following order: visual probe (125 min), MPSS and
TCQ-SF (150min), picture rating task (155min), phonological, se-
mantic and drug fluency (160min). Participants were reimbursed
£7.50 per hour and were able to earn additional money during the
testing session (see Freeman et al., 2012b) but were not instructed that
they could earn additional money in any of the tasks reported here.
Preparation of eye movement and manual RT data for the
visual probe task
Eye movements were recorded at a 1 kHz sampling rate, using a desk-
top mounted EyeLink 1000 eye tracking device (SR Research, Ontario,
Canada). Participants were seated with their head in a chin/forehead
rest 70 cm away from a 19-inch LCD monitor used to present the
stimuli. Prior to recording, participants’ eye movements were cali-
brated by fixation on a 3 3 point grid. Drift correction was per-
formed between each trial to ensure participants were attending to
the centre of the screen before stimulus onset. Initial orienting of at-
tention was calculated as the proportion of trials in which the first
fixation was directed towards the reward image, with 0.5 indicating no
bias, and scores above/below 0.5 reflecting increased/decreased bias,
respectively. These scores were calculated using all trials in which at
least one fixation was made to the reward or control image. Fixations
occurring between 0 and 100ms after stimulus onset were removed
(excluding <0.1% of trials) to eliminate any anticipatory eye move-
ments that are not caused by stimulus exposure (e.g. Mogg et al., 2003;
Field et al., 2004; Bradley et al., 2007). Mean fixation latencies are
typically 300–400ms (Mogg et al., 2003), and so data were only
available for 21.1% of 250ms trials, but for 91.9% of 2000ms trials.
Dwell time data were restricted to 2000ms trials only using the same
criteria (91.9% of trials) and were calculated as the summed duration
(ms) of fixation time to each image (reward and control) on each trial.
Analysis of behavioural data included RTs from 250 and 2000ms trials
and following previous research (Bradley et al., 2007), these were
excluded if an incorrect response was made (11.7% of data), if they
were <200ms, >1000ms, and then 3 s.d. from each participant’s
mean for each Type and Target (0.7% of data). Bias scores were cal-
culated by subtracting RTs on congruent trials (where the probe
replaced a reward image) from incongruent trials (where the probe
replaced a control image), with positive/negative scores indicating bias
towards/away from reward images, respectively.
Statistical analysis
Paired sample t-tests and repeated measures analysis of variance
(ANOVA) models were used to assess effects of Treatment (prami-
pexole, placebo). Fluency tasks were analysed using planned orthog-
onal contrasts comparing (i) drug-related (smoking) with non-drug
(phonological and semantic) fluency, (ii) phonological and semantic
fluency. All analysis of the visual probe data included an extra within-
subject factor of Type (smoking, money) with additional factors of
Stimulus (reward, control) for dwell time and picture rating, and
Trial (250 and 2000ms) for RT bias scores. Time (pre, post) was a
within-subject factor for analysis of the MPSS and the TCQ-SF. One
sample t-tests were used to assess whether biases in initial orienting
occurred towards smoking or money reward images versus control
images, using a test value of 0.5 (no bias), and were also used to
assess any significant RT bias scores using test value of 0 (no bias).
Post hoc t-tests and Pearson correlation analyses were two-tailed unless
stated and a Bonferroni correction was applied locally within each
ANOVA model. Baseline dependency refers to an inverse relationship
between basal scores (placebo) and the direction and magnitude of
treatment effects (scores on pramipexolescores on placebo) and
was investigated using Pearson correlational analyses. In the absence
of test–retest reliability scores (Teicher et al., 2003), we investigated
whether these effects were robust to regression to the mean artefacts
using a method described by Myrtek and Foerster (1986). This ap-
proach has previously been used to establish baseline dependency in
experimental studies of this kind (Mehta et al., 2004) and is evidenced
by a significant t statistic. In all tables and figures, *P< 0.05, **P< 0.01,
***P<0.001, and error bars show SEM.
RESULTS
Participants and smoking behaviour
Participants’ mean (s.d.) age was 24.81 (4.92) years. They reported
smoking for 8.25 (5.21) years and were currently smoking 13.25
(4.64) cigarettes per day. FTND scores were 4.81 (1.17) indicating
moderate levels of nicotine dependence. MTSS scores were 4.38
(1.15) reflecting intermediate motivation to stop (e.g. ‘I REALLY
want to stop smoking but I don’t know when I will’). Expired CO
levels (Parts Per Million) did not differ before treatment with placebo
(15.63 6.75) and pramipexole (15.75 4.63). Fidelity of the blind
was maintained with neither participant nor experimenter guesses dif-
fering from chance on either day (all 21’s < 1.1, all P’s > 0.3). For data
on subjective effects, see Freeman et al. (2012b). Briefly, pramipexole
administration was associated with an increase in drowsiness, and a
more pronounced reduction in Positive Affect than that seen on pla-
cebo. These effects are consistent with previous findings in healthy
volunteers at this dose (e.g. Hamidovic, King and de Wit, 2008).
Visual probe task
For initial orienting (Figure 2), a TreatmentType interaction
(F1,15¼ 6.197, P¼ 0.025, 2p¼ 0.292) emerged as well as a main effect
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of Type (F1,15¼ 9.294, P¼ 0.008, 2p¼ 0.383). Pramipexole reduced
attentional bias on smoking trials (t15¼ 1.866, P¼ 0.041, one-tailed
as hypothesised) but not money trials (t15¼ 1.632, P¼ 0.124).
Further exploration of the interaction showed that on placebo, a
greater bias in orienting towards reward images was shown on smoking
compared with money trials (t15¼ 3.911, P< 0.001) but after prami-
pexole no difference was evident between these two trial types
(t15¼ 0.147, P¼ 0.885). Significant bias scores (i.e. different from
0.5) were shown towards smoking reward images (t15¼ 5.561,
P< 0.001) but not money reward images (t15¼ 0.295, P¼ 0.772) on
placebo. After pramipexole, significant bias scores were found for both
smoking (t15¼ 2.180, P¼ 0.046) and money (t15¼ 2.546, P¼ 0.022)
reward images.
Analysis of dwell time (Figure 3) revealed a trend for a
Type Stimulus interaction (F1,15¼ 4.282, P¼ 0.056, 2p¼ 0.222) as
well as main effects of Type (F1,15¼ 51.181, P< 0.001, 2p¼ 0.773)
and Stimulus (F1,15¼ 11.530, P¼ 0.004, 2p¼ 0.435). Exploration of
the interaction revealed significantly greater dwell time for reward
versus control images on smoking trials (t15¼ 3.898, P<0.001) but
not on money trials (t15¼ 1.742, P¼ 0.102). Manual RT bias scores
were missing for one participant on the placebo day due to use of
incorrect response keys on the task. Analysis of RT bias in the remain-
ing 15 participants (Table 1) did not reveal any significant interactions
or effects of Day, Type or Trial, and none of the bias scores were
significantly different from 0. Although RT bias scores were only cal-
culated from trials in which a correct response to the probe was made,
exploratory analysis indicated that significantly more errors were made
on pramipexole (14.83 7.94%) compared with placebo (8.63
4.19%), t15¼ 3.919, P¼ 0.002. Controlling for differences in probe
response errors by including it as a covariate in each of the previous
models (initial fixation, dwell time, RT bias) did not change any of the
results, and did not reveal any new effects or interactions. This suggests
that variation in probe accuracy did not influence these results.
Picture rating task
A significant Type Stimulus interaction emerged (F1,15¼ 8.517,
P¼ 0.011, 2p¼ 0.362), as well as a main effect of Stimulus
(F1,15¼ 39.009, P< 0.001, 2p¼ 0.722) and a trend for a main effect
of Type (F1,15¼ 4.183, P¼ 0.059, 2p¼ 0.218) (Table 1). No
TreatmentType Stimulus interaction was found (F1,15¼ 1.582,
P¼ 0.228, 2p¼ 0.095). The Type Stimulus interaction indicated
that equal pleasantness ratings were given towards smoking and
money control images (t15¼ 1.041, P¼ 0.314) but higher pleasantness
ratings were made towards money relative to smoking reward images
(t15¼ 2.899, P¼ 0.011).
Fluency tasks
A significant interaction was found between Treatment and the con-
trast comparing drug fluency with non-drug fluency performance
(F1,15¼ 5.363, P¼ 0.035, 2p¼ 0.263) (Figure 4). Phonological and se-
mantic fluency scores did not differ from each other or interact with
Treatment. The only other effect to emerge was a trend for lower drug
fluency compared with non-drug fluency on both testing days
(F1,15¼ 4.051, P¼ 0.062, 2p¼ 0.213). Exploration of the interaction
showed that performance on the phonological and semantic fluency
tasks did not differ across the two testing days (t15¼ 0.404, P¼ 0.692)
but fewer smoking-related words were generated after pramipexole
compared with placebo (t15¼ 2.705, P¼ 0.008, one-tailed as
hypothesised).
Table 1 Mean (s.d.) scores for behavioural data from the visual probe and picture rating
tasks
Placebo Pramipexole
Visual probe RT bias
Money
250 ms 1.57 (19.54) 6.61 (22.52)
2000 ms 0.33 (24.46) 9.00 (27.98)
Smoking
250 ms 1.01 (23.20) 2.75 (26.66)
2000 ms 3.46 (22.14) 3.20 (28.24)
Picture rating
Money
Control 0.11 (0.72) 0.11 (0.60)
Reward 1.75 (0.85) 1.66 (0.82)
Smoking
Control 0.21 (0.38) 0.33 (0.35)
Reward 1.26 (1.06) 0.68 (1.36)
Fig. 2 Initial orienting towards reward-based images. Pramipexole decreased attentional bias to-
wards smoking images, redressing an imbalance between the salience of drug versus non-drug
reward. Significant bias scores are marked with an asterisk above the x axis.
Fig. 3 Maintained attentional bias. Smokers showed longer dwell time towards reward images
compared with control images on smoking trials, but equivalent dwell time was observed towards
both types of image on money trials.
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Mood, physical symptoms and tobacco craving
Analysis of the MPSS revealed significant effects of Time for ‘Irritable’,
‘Restless’, ‘Hungry’ and ‘Poor concentration’, reflecting increased se-
verity of symptoms post-drug compared with pre-drug (Table 2).
Analysis of Strength of Urges to Smoke (SUTS) revealed a significant
Time  Treatment interaction (2p¼ 0.327); SUTS decreased from pre-
to post-pramipexole treatment (t15¼ 2.334, P¼ 0.017 one-tailed as
hypothesised) but tended to increase with Time on the placebo day
(t15¼ 1.952, P¼ 0.035 one-tailed).
For the Tobacco Craving Questionnaire, significant effects of Time
emerged for ‘Emotionality’, ‘Expectancy’, ‘Purposefulness’ and total
scores, reflecting elevated craving scores post-drug compared with
pre-drug. For Compulsivity, main effects of Time and Day were
found. Although a significant Time  Treatment interaction did not
emerge for the Compulsivity subscale, lower craving scores on the
pramipexole day compared with placebo appeared to be driven by
post-treatment ratings (t15¼ 2.389, P¼ 0.030) whereas pre-treatment
scores did not differ across the two testing days (t15¼ 1.497,
P¼ 0.155).
Exploring individual variability in drug effects
Pearson correlational analyses were carried out between treatment ef-
fects (pramipexole minus placebo scores) on the following variables:
initial orienting to money reward images, initial orienting to smoking
reward images, drug fluency and the changes in SUTS across the test-
ing session. No significant correlations emerged. Furthermore, none of
these variables correlated with treatment effects on side effects experi-
enced (increases in drowsiness and decreases in Positive Affect). Thus,
the observed results cannot be accounted for by these side effects.
Additionally, independent sample t-tests indicated that treatment ef-
fects were equivalent in both male and female volunteers.
Baseline dependency (the relationship between initial scores and
changes scores) was also investigated. Placebo scores were inversely
related to the direction and magnitude of effects for initial orienting
to money reward images (r¼0.848, P< 0.001), initial orienting to
smoking reward images (r¼0.777, P<0.001), and the changes in
SUTS across the testing session (r¼0.828, P< 0.001) but not drug
fluency (r¼0.482, P¼ 0.059). Using a method described by Myrtek
and Foerster (1986) to control for regression to the mean artefacts,
these findings were robust for initial orienting towards money
(t15¼ 31.571, P< 0.001; Figure 5a) and smoking (t15¼ 13.245,
P< 0.001; Figure 5b) but not SUTS (t15¼ 0.846, P¼ 0.409).
DISCUSSION
In tobacco smokers, a single 0.5mg dose of pramipexole attenuated a
bias in initial orienting towards images of smoking relative to money,
redressing an imbalance between the salience of drug versus non-drug
reward. No effects were found for dwell time, which accords with
previous within-subject manipulations in smokers producing dissoci-
able effects for initial and maintained attentional bias (Field et al.,
2004; Bradley et al., 2007). Furthermore, RT bias was lacking alto-
gether, perhaps due to the poorer internal reliability of these indirect
measures (Ataya et al., 2011; Field and Christiansen, 2012). Decreases
in retrospective urges to smoke, and smoking-related word production
were also found, but state tobacco craving scores were unaffected by
pramipexole. Although these effects did not correlate with each other,
they provide the first evidence that manipulating the dopamine system
can elicit reward-specific effects on attentional bias and produce cor-
responding changes in drug-related urges and cognitive bias.
Initial orienting towards smoking images decreased after pramipex-
ole, in line with its agonist action at presynaptic autoreceptors (Maj
et al., 1997; Pizzagalli et al., 2008), causing a reduction in phasic dopa-
mine firing to drug cues (Phillips et al., 2003). However, the contrast-
ing effects on money stimulia non-significant increasecannot be
Table 2 Mean (s.d.) scores for mood and physical symptoms, smoking urges and craving at baseline and 150 min after treatment
Placebo Pramipexole Time Treatment F(1,15) Time F(1,15) Treatment F(1,15)
Pre Post Pre Post
MPSS depressed 0.19 (0.40) 0.06 (0.25) 0.31 (0.60) 0.13 (0.34) 0.319 4.310 0.808
MPSS irritable 0.06 (0.25) 0.25 (0.58) 0.19 (0.54) 0.44 (0.63) 0.072 4.623* 1.518
MPSS restless 0.38 (0.50) 1.06 (0.68) 0.50 (0.73) 1.19 (1.17) 0.000 12.020** 0.484
MPSS hungry 0.57 (0.63) 1.81 (0.83) 0.57 (0.63) 1.81 (0.91) 0.000 31.250*** 0.00
MPSS poor concentration 0.44 (0.63) 1.13 (0.81) 0.44 (0.51) 1.38 (0.81) 0.652 18.778*** 0.484
MPSS time spent with urges 2.06 (0.85) 1.94 (1.29) 2.06 (0.68) 1.69 (0.70) 0.319 2.500 0.385
MPSS SUTS 1.94 (0.85) 2.50 (1.32) 2.44 (0.73) 1.88 (0.72) 7.275* 0.00 0.048
TCQ emotionality 8.66 (3.94) 10.72 (5.87) 7.60 (3.93) 10.06 (5.63) 0.078 5.249* 0.718
TCQ expectancy 14.03 (4.28) 18.06 (3.33) 13.28 (3.97) 15.53 (4.54) 1.575 17.833*** 1.903
TCQ compulsivity 8.25 (4.86) 11.94 (6.05) 6.41 (3.04) 8.91 (4.50) 0.951 18.490*** 4.985*
TCQ purposefulness 12.28 (4.97) 14.66 (4.83) 11.94 (3.23) 13.66 (3.99) 1.390 7.080* 0.501
TCQ total 43.22 (14.05) 55.38 (17.61) 39.22 (10.22) 48.16 (15.34) 0.921 13.995** 2.268
Fig. 4 Fluency tasks. Fewer smoking-related words were generated for the drug fluency task on
pramipexole compared with placebo, but non-drug (phonological and semantic) fluency did not differ
across treatment days.
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easily explained in this way. Perturbations of the dopamine system can
have differential effects on cognition that are dependent on baseline
state and motivation (Aarts et al., 2011; Cools and D’Esposito, 2011).
Attentional bias towards smoking images was markedly evident on
placebo, reflecting the strong incentive-motivational properties of
drug cues in addicted individuals (Robinson and Berridge, 1993). If
they were able to elicit phasic dopamine release because of their be-
havioural relevance (Grace, 1991), these cues should also be sensitive to
autoreceptor self-regulation by a dopamine agonist, decreasing atten-
tional bias. In contrast, there was no evidence of bias towards money
on placebo, perhaps due to a low level of motivation towards this non-
drug reward (Anselme, 2009; Bu¨hler et al., 2010; Goldstein and
Volkow, 2011). If these images were unable to elicit phasic dopamine
release to start with, this may have rendered them ineffective to self-
regulation by pramipexole.
Exploration of individual differences showed that the direction and
magnitude of treatment effects on attentional bias were inversely
related to scores on placebo, after controlling for regression to the
mean. Thus, orienting towards smoking images decreased most in
those with the strongest bias on placebo, but conversely increased in
those with no bias to begin with. At the same time, money bias under-
went the greatest increase in people who oriented away from it on
placebo, but diminished in those who were initially biased towards
it. This suggests that dopamine has an ‘inverted U-shaped’ profile in
addiction (as reported for working memory and cognitive control;
Cools and D’Esposito, 2011), with separate curves for drug and non-
drug reward. Thus, dopaminergic pharmacotherapies might worsen or
improve outcomes in addiction depending on the dose and the indi-
vidual. This could explain why bupropion, an effective dopaminergic
treatment for smoking cessation, can paradoxically increase smoking in
people who are not motivated to quit (Cousins et al., 2001). Opposite
effects of dopaminergic agents may be caused by changes in the sen-
sitivity of pre-synaptic and post-synaptic dopamine receptors (Cools
and D’Esposito, 2011), perhaps mediating reductions and increases in
attentional bias respectively following a D2/D3 agonist in this study.
However, the mechanisms responsible for our results are speculative,
and future studies should employ additional doses in order to dissoci-
ate pre-synaptic and post-synaptic effects (Maj et al., 1997).
In people seeking treatment for addiction, preferential reactivity to
drug-related compared with other rewarding or pleasant stimuli pre-
dicts poorer outcomes at follow up (Lubman et al., 2009; Versace et al.,
2011). As baseline attentional bias was inversely related to drug effects,
this may indicate that people with the severest imbalance between drug
and non-drug reward might benefit most from drugs such as prami-
pexole. One qualification of the claim that pramipexole redressed this
imbalance is that we did not place smoking and money images along-
side each other during the visual probe task. However, because drug
cues can overshadow other reward-predicting stimuli (Freeman et al.,
2012a) one might expect that interventions such as pramipexole could
be most effective in contexts where drug and non-drug reward cues are
in direct competition with each other. Based on the findings reported
here, drugs such as pramipexole might be particularly useful for
acutely reducing reactivity to drug-associated cues, a quality that
may be lacking in current smoking cessation pharmacotherapies
(Hitsman et al., 2012). In contrast to previous work (Munafo` et al.,
2007), we found equivalent results in male and female volunteers.
The results of this study add to previous evidence highlighting the
potential of dopamine agonists for smoking cessation (Caskey et al.,
1999, 2002; Jarvik et al., 2000). Additionally, a substantially lower rate
of smoking (<50%) was seen at antenatal booking in those who used
the dopamine D2 agonist bromocriptine to aid conception versus other
methods or no treatment (Murphy et al., 2002). However, it should be
noted that nausea and drowsiness are common side effects of these
drugs and based on previous research (Ersche et al., 2010), we admin-
istered a single low (0.5mg) dose of pramipexole with the peripheral
dopamine antagonist domperidone (30mg). This was effective in
alleviating any increases in nausea but drug treatment did enhance
drowsiness and potentiated a general reduction in Positive Affect in
the sample of smokers tested here (see Freeman et al., 2012b).
Moreover, pramipexole reduced overall accuracy for responses on
the visual probe task. Although these side effects and impairments
were not associated with any of the other treatment effects found in
this study, future work should investigate the consequences of ex-
tended dosing with drugs such as pramipexole, at even lower doses
which may not induce side effects (Hamidovic et al., 2008) and in
smokers who are motivated to quit.
Participants were required to remain abstinent during each testing
session in this study, but despite this manipulation and in contrast to
placebo, pramipexole-treated smokers showed a reduction in SUTS.
The SUTS item is thought to be especially sensitive to peak craving
experiences such as smoking cue exposure due to its retrospective
nature (Ferguson et al., 2011) and a single rating on this item from
a day’s smoking is highly predictive of cessation success 6 months later
(Fidler et al., 2011).
Fig. 5 Baseline dependency. Variation in individuals’ performance on the placebo day was predictive of the direction and magnitude of drug effects for initial orienting to (A) money and (B) smoking. These
effects were reliable when controlling for regression to the mean.
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Because this item was rated retrospectively after the visual probe
task, an enhanced sensitivity to peak craving experiences (Ferguson
et al., 2011) might offer some explanation for this effect, in the absence
of changes on ‘in the moment’ scores from the Tobacco Craving
Questionnaire. On the other hand, reductions in urges to smoke and
tobacco craving have been reported following dopamine agonist treat-
ment in the absence of experimental smoking cues (Caskey et al., 1999,
2002; Jarvik et al., 2000). These issues could be explored further by
manipulating both dopaminergic function and cue presentation in a
factorial design.
Another finding of this study was that pramipexole reduced drug
fluency, which is theoretically related to attentional bias (Goldstein
et al., 2007) and correlates with drug-cue elicited BOLD activation in
dopamine innervated mesotelencephalic brain regions (Goldstein
et al., 2009). Incentive salience theory provides a strong theoretical
background to attentional bias research (Field and Cox, 2008) and
the parallel decreases in initial orienting, drug fluency, and smoking
urges suggest that drug-related ‘wanting’ and attentional bias are
subserved by a common dopaminergic system (Robinson and
Berridge, 1993). In contrast to previous studies on dopamine and
attentional bias (Franken et al., 2004; Munafo` et al., 2007; Hitsman
et al., 2008; Ersche et al., 2010; Luijten et al., 2012), our study is the
first to our knowledge showing that these effects may be accompa-
nied by corresponding changes in urges and drug-related cognition,
as predicted by Franken (2003). Additionally, results from the picture
rating task indicated that money images were rated as more pleasant
than smoking images; the contrasting results for these ratings and
overt attention to the same cues supports a dissociation between
motivational ‘wanting’ and hedonic ‘liking’ processes in addiction
(Robinson and Berridge, 1993).
On the other hand, pramipexole did not influence maintained at-
tentional bias or state tobacco craving, and the effects on initial ori-
enting, drug fluency and smoking urges did not correlate. Thus, not all
of these results support a unitary underlying mechanism, and suggest
these processes might be independent or at least dissociable.
Furthermore, they could be interpreted in other ways. One major al-
ternative hypothesis is that phasic dopamine release follows the differ-
ence between expected and actual reward delivery and acts as a
teaching signal in reinforcement learning (Schultz et al., 1997). One
way to distinguish between ‘motivational’ and ‘learning’ based ac-
counts of dopamine might be to test whether the effects we observed
are moderated by state physiological changes (Berridge, 2012) such as
tobacco abstinence, which can increase attentional bias to smoking
cues (Field et al., 2004; Freeman et al., 2012a).
STUDY LIMITATIONS
We acknowledge that the use of ‘smoking’ and ‘money’ images can
only provide a crude index of reward processing that may be depend-
ent on the nature of specific images and individual differences across
volunteers. Although the interactive effects of treatment and picture
type in this design cannot be attributed to these cross-sectional factors,
future studies should aim to investigate these effects using a range of
other reward-based stimuli. Furthermore, similar to other studies of
this kind (Franken et al., 2004; Munafo` et al., 2007; Hitsman et al.,
2008; Ersche et al., 2010), the relatively small sample size in this study
is an important limitation. Finally, volunteers were prohibited from
smoking during the testing session, therefore we cannot ascertain
whether similar effects would be shown under different conditions of
nicotine deprivation. Future studies should investigate the effects of
pramipexole in larger samples, at different levels of tobacco abstinence,
and in different subgroups of smokers.
CONCLUSIONS
A single dose of pramipexole can alleviate a bias in initial orienting to
drug cues versus other rewards in smokers. These effects were inversely
related to baseline scores, supporting an ‘inverted U’ profile of dopa-
mine in addiction. State tobacco craving was unaffected, but simultan-
eous reductions were found for SUTS and drug-related fluency. These
findings highlight an important role for D2/D3 receptor function in
nicotine dependence and its treatment.
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